Accueil › Cancer du poumon › Washington › Seattle
Essais cliniques pour Cancer du poumon à Seattle, WA
33 études pour Cancer du poumon recherchent des participants dans et autour de Seattle (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Recrutement en coursPhase 1/2
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- et 1 autres
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Recrutement en coursPhase 3
- Swedish Medical Center-First Hill, Seattle
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Recrutement en coursPhase 1
- Fred Hutchinson Cancer Center, Seattle
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Recrutement en coursPhase 3
- Swedish Medical Center-First Hill, Seattle
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Recrutement en coursPhase 3
- University of Washington - Fred Hutchinson Cancer Center, Seattle
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Recrutement en coursPhase 1/2
- Swedish Medical Center, Seattle
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Recrutement en coursPhase 2/3
- Fred Hutchinson Cancer Center, Seattle
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Recrutement en coursPhase 2
- Research Site, Seattle
A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial
Recrutement en coursVolontaires sains bienvenus
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Recrutement en coursPhase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Recrutement en coursPhase 3
- Swedish Medical Center, Seattle
- VA Puget Sound Health Care System, Seattle
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Recrutement en coursPhase 1/2
- Avenzo Therapeutics Recruiting Site, Seattle
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Recrutement en coursPhase 1
- Fred Hutchinson Cancer Center, Seattle
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
Recrutement en coursPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Recrutement en coursPhase 3
- Virginia Mason Medical Center, Seattle
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
Recrutement en coursPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
Recrutement en cours
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Recrutement en coursPhase 1
- Fred Hutchinson Cancer Center, Seattle
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Recrutement en coursPhase 1
- Xencor Investigative Site, Seattle
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Recrutement en coursPhase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Recrutement en coursPhase 1/2
- Fred Hutch Cancer Center, Seattle
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Recrutement en coursPhase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Recrutement en coursPhase 2
- Seattle Cancer Care Alliance, Seattle
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
Recrutement en coursPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Recrutement en coursPhase 1/2
- Fred Hutchinson Cancer Center, Seattle
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Recrutement en coursPhase 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- FHCC at Northwest Hospital, Seattle
- et 1 autres
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Recrutement en coursPhase 1/2
- Virginia Mason Medical Center, Seattle
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Recrutement en coursPhase 2
- Swedish Medical Center-First Hill, Seattle
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Recrutement en coursPhase 1/2
- Virginia Mason Medical Center, Seattle
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Recrutement en coursPhase 1
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recrutement en coursÉtude observationnelle
- Massive Bio SYNERGY-AI site, Seattle
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Recrutement en coursPhase 1/2
- Fred Hutch Cancer Center, Seattle
Essais pour Cancer du poumon dans d'autres villes
- Houston, TX78 études
- Boston, MA62 études
- New York City, NY60 études
- Los Angeles, CA45 études
- Washington, DC41 études
- Arlington, VA41 études
- Chicago, IL41 études
- Nashville, TN40 études
- Baltimore, MD40 études
- St. Louis, MO39 études
- Columbus, OH37 études
- Philadelphia, PA36 études
Autres études à Seattle
- Cancer du poumon non à petites cellules53 études
- Cancer (tous types)49 études
- Cancer de la prostate42 études
- Leucémie aiguë myéloïde40 études
- Cancer du sein39 études
- Cancer métastatique39 études
- Cancer colorectal34 études
- Cancer de l'ovaire30 études
- Myélome multiple22 études
- Syndromes myélodysplasiques21 études
- Leucémie aiguë lymphoblastique21 études
- Cancer de la vessie21 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.